Sorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma: A phase II study

Oncology Letters

Volumn 8, Issue 4, 2014, Pages 1783-1787

  Gadaleta Caldarola, Gennaro ^a   Infusino, Stefania ^b   Galise, Ida ^a   Ranieri, Girolamo ^a   Vinciarelli, Gianluca ^a   Fazio, Vito ^a   Divella, Rosa ^a   Daniele, Antonella ^a   Filippelli, Gianfranco ^b   Gadaleta, Cosmo Damiano ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b Medical Oncology Unit 'S Francesco di Paola' Hospital ^*  (Italy)

Author keywords

Carcinoma; Electro hyperthermia; Hepatocellular; Sorafenib

Indexed keywords

SORAFENIB;

ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HEPATITIS VIRUS; HUMAN; HYPEREMIA; HYPERTENSION; HYPERTHERMIA; LIVER CELL CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SKIN ALLERGY; TREATMENT RESPONSE; VOMITING;

EID: 84928887624     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2376     Document Type: Article

References (24)

1. Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet 379: 1245-1255, 2012.
3. European Association For The Study Of The Liver1; European Organisation For Research And Treatment Of Cancer: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56: 908-943, 2012.
4. Ranieri G, Gadaleta-Caldarola G, Goffredo V, et al: Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development. Curr Med Chem 19: 938-944, 2012.
5. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
6. Cheng AL, Kang YK, Chen Z, Tsao CJ, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.
7. Fiorentini G and Szasz A: Hyperthermia today: electric energy, a new opportunity in cancer treatment. J Cancer Res Ther 2: 41-46, 2006.
8. Roca C, Primo L, Valdembri D, et al: Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism. Cancer Res 63: 1500-1507, 2003.
9. Hildebrandt B, Wust P, Ahlers O, et al: The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 43: 33-56, 2002.
10. van der Zee J: Heating the patient: a promising approach? Ann Oncol 13: 1173-1184, 2002.
11. Horsman MR: Angiogenesis and vascular targeting: relevance for hyperthermia. Int J Hyperthermia 24: 57-65, 2008.
12. Ranieri G, Catino A, Mattioli V, et al: Targeting tumour vascularization from bench to bedside: Some suggestions for combination with hyperthermia. In: Cancer Microenvironment and Therapeutic Implications. Baronzio G, Fiorentini G and Cogle CR (eds). 1st edition. Springer Science + Business Media B. V, Dordrecht, pp203-219, 2009.
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
14. Bruggmoser G, Bauchowitz S, Canters R, Crezee H, et al; ESHO Technical Committee in the Interdisciplinary Working Group Hyperthermia (IAH) in the German Cancer Society: Quality assurance for clinical studies in regional deep hyperthermia. Strahlenther Onkol 187: 605-610, 2011.
15. NCI: Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/forms/CTCAE v3.pdf. Accessed January 8, 2009.
16. Lacouture ME, Wu S, Robert C, Atkins MB, et al: Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13: 1001-1011, 2008.
17. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, et al: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293-4300, 2006.
18. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed August 9, 2006.
19. Yuan GJ, Li QW, Shan SL, et al: Hyperthermia inhibits hypoxia-induced epithelial-mesenchymal transition in HepG2 hepatocellular carcinoma cells. World J Gastroenterol 18: 4781-4786, 2012.
20. Xu XM, Yuan GJ, Li QW, Shan SL and Jiang S: Hyperthermia inhibits transforming growth factor beta-induced epithelial-mesenchymal transition (EMT) in HepG2 hepatocellular carcinoma cells. Hepatogastroenterology 59: 2059-2063, 2012.
21. Mayrhauser U, Stiegler P, Stadlbauer V, Koestenbauer S, et al: Effect of hyperthermia on liver cell lines: important findings for thermal therapy in hepatocellular carcinoma. Anticancer Res 31: 1583-1588, 2011.
22. Ferrari VD, De Ponti S, Valcamonico F, et al: Deep electro-hyperthermia (EHY) with or without thermo-active agents in patients with advanced hepatic cell carcinoma: Phase II study. J Clin Oncol 25 (S): Abstract 15168, 2007.
23. Krawczyka PM, Eppinkb B, Essers J, Stap J, et al: Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci USA 24: 9851-9856, 2011.
24. Gadaleta CD, Catino A, Ranieri G, Fazio V, et al: Single-step therapy-feasibility and safety of simultaneous transarterial. chemoembolization and radiofrequency ablation for hepatic malignancies. In vivo 23: 813-820, 2009.